Momenta sues Teva over enoxaparin patents
Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) filed suit against Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) in the U.S. District Court for the District of Massachusetts alleging that Teva's generic enoxaparin infringes two of Momenta's patents covering the production of enoxaparin. Teva, which has an ANDA for generic enoxaparin under review at FDA, said the suit is "without merit" and claims its product does not infringe the patents. In July, FDA approved an ANDA from Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) and partner Sandoz, the generics unit of Novartis AG (NYSE:NVS; SIX:NOVN), for a generic version of anticoagulant Lovenox enoxaparin, a low-molecular weight heparin from sanofi-aventis Group (Euronext:SAN; NYSE:SNY). Novartis reported $292 million in 3Q10 sales for the product. Momenta was up $0.23 to $15.65 on Thursday. ...